Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can lower chemo doses help older cancer patients?

NCT ID NCT06840977

Knowledge-focused Sponsor: Matteo Clavarezza Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study looks at medical records of 51 patients aged 70 and older with metastatic colorectal cancer. Researchers want to see if using lower doses of chemotherapy along with full-dose targeted therapy can reduce serious side effects like low white blood cell counts and severe diarrhea. The goal is to find a safer treatment option for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose safer, more effective chemotherapy doses for elderly patients with metastatic colorectal cancer.
What could go wrong
This is a small, retrospective study that only looks back at past cases, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 51 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes patients aged 70 years and older, with metastatic colorectal adenocarcinoma, MSS, BRAF WT, with a G8 score greater than or equal to 12, candidates for metastatic first-line treatment

Ages

70 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted. 2. Age ≥ 70 years 3. G8 score ≥ 12 4. Patients with colorectal adenocarcinoma MSS 5. Patients with BRAF WT colorectal adenocarcinoma 6. Ability to understand and sign the informed consent form. Exclusion Criteria: 1. Patients with MSI tumours 2. Patients with BRAF V600E mutated tumours 3. Patients not eligible for doublet chemotherapy by clinical decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm colorectal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • E.O. Ospedali Galliera

    RECRUITING

    Genova, GE, 16128, Italy

  • E.O. Ospedali Galliera

    NOT_YET_RECRUITING

    Genoa, Liguria, 16128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.